Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Ro

Kin Meds
Graded #73

Lower grade

vs+7.299999999999997
Ro
Graded #38

Higher grade

The verdict

Ro takes it — 80.2/100 to 72.9/100.

Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +6
74
68
Dose & formulationKin Meds +7
93
86
Clinical oversightRo +12
74
86
Labs & monitoringRo +29
53
82
FulfillmentRo +12
72
84
Contract termsRo +25
55
80
Kin Meds · left barRo · right bar

The numbers

MetricKin MedsRo
WeighScore72.9/10080.2/100
GradeCB−
Scorecard rank#73#38
Semaglutide$149/mo (brand Wegovy)Not disclosed
Tirzepatide$149/mo (brand Zepbound)Not disclosed
CoverageCoverage not publishedMulti-state
Brand-name accessYesYes
Oral / sublingualYesYes
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Ro

Graded #38 · B−

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Well-funded platform

Where it loses points

  • Does not disclose compounded pricing up front
  • Premium positioning

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard